-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Iz2heo+KZSsB7noLm1jmqUiJl6HaVK6/qw5fFYa7XfQ5W+XnN7Nd2wURb/eVNa6W n6yJAOKg0Z8dkEcwkQZcPA== 0000950135-07-003704.txt : 20070615 0000950135-07-003704.hdr.sgml : 20070615 20070615162907 ACCESSION NUMBER: 0000950135-07-003704 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070613 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20070615 DATE AS OF CHANGE: 20070615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000861838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043072298 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31918 FILM NUMBER: 07923363 BUSINESS ADDRESS: STREET 1: 345 VASSAR STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6176795500 MAIL ADDRESS: STREET 1: 345 VASSAR STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: HYBRIDON INC DATE OF NAME CHANGE: 19951211 8-K 1 b65747ipe8vk.htm IDERA PHARMACEUTICALS, INC. e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): June 13, 2007
Idera Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Charter)
         
Delaware   001-31918   04-3072298
         
(State or Other Jurisdiction
of Incorporation) 		  (Commission File Number)   (IRS Employer Identification No.)
     
167 Sidney Street, Cambridge, Massachusetts   02139
     
(Address of Principal Executive Offices)   (Zip Code)
Registrant’s telephone number, including area code: (617) 679-5500
345 Vassar Street, Cambridge, Massachusetts
 
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
SIGNATURE

Table of Contents

Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     On June 13, 2007, at the Annual Meeting of Stockholders of Idera Pharmaceuticals, Inc, Idera’s stockholders approved an amendment to its 2005 Stock Incentive Plan increasing the number of shares of common stock authorized for issuance under the plan from 1,125,000 shares to 2,625,000 shares. The amended 2005 Stock Incentive Plan, as approved by Idera’s Board of Directors, was attached as Appendix A to the proxy statement filed with the Securities and Exchange Commission on April 30, 2007. A summary of the amended 2005 Stock Incentive Plan’s terms was provided in such proxy statement and is incorporated herein by reference.

 

Table of Contents

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  IDERA PHARMACEUTICALS, INC.
 		  
Date: June 15, 2007  By:   /s/ Robert G. Andersen   
    Robert G. Andersen   
    Chief Financial Officer   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----